

Ole Schmeltz SÃ¸gaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1967788/publications.pdf>

Version: 2024-02-01

97
papers

4,664
citations

126907

33
h-index

110387

64
g-index

101
all docs

101
docs citations

101
times ranked

6083
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1126-1133.	6.0	30
2	The level of naturally occurring anti- α -Gal antibody predicts antibody response to polysaccharide vaccination in HIV-1 infected adults. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e13008.	2.7	1
3	SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. <i>Thorax</i> , 2021, 76, 370-379.	5.6	15
4	Persistent Symptoms in Patients Recovering From COVID-19 in Denmark. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab042.	0.9	47
5	Venous Thromboembolism and Major Bleeding in Patients With Coronavirus Disease 2019 (COVID-19): A Nationwide, Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2283-2293.	5.8	44
6	SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. <i>EBioMedicine</i> , 2021, 64, 103230.	6.1	113
7	Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity. <i>EBioMedicine</i> , 2021, 65, 103255.	6.1	256
8	Deciphering the association between HIV-specific immunity and immune reconstitution. <i>EBioMedicine</i> , 2021, 67, 103350.	6.1	2
9	Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.. <i>EClinicalMedicine</i> , 2021, 35, 100849.	7.1	146
10	Improved Survival Among Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) Treated With Remdesivir and Dexamethasone. A Nationwide Population-Based Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 2031-2036.	5.8	68
11	TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure. <i>Frontiers in Immunology</i> , 2021, 12, 704617.	4.8	8
12	First wave of COVID-19 hospital admissions in Denmark: a Nationwide population-based cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 39.	2.9	26
13	The Impact of IFN γ on the Adaptive Immune Response to SARS-CoV-2 Infection. <i>Journal of Interferon and Cytokine Research</i> , 2021, 41, 407-414.	1.2	3
14	HIV-1 acquisition in a man with ulcerative colitis on anti- α -4 β 7 mAb vedolizumab treatment. <i>Aids</i> , 2020, 34, 1689-1692.	2.2	0
15	Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 309-315.	3.8	17
16	The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1112.	4.8	44
17	Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e017297.	3.7	7
18	Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice. <i>PLoS ONE</i> , 2020, 15, e0241375.	2.5	7

#	ARTICLE	IF	CITATIONS
19	TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes. <i>EBioMedicine</i> , 2019, 45, 328-340.	6.1	22
20	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. <i>Journal of Virology</i> , 2019, 93, .	3.4	49
21	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	4.7	139
22	DC-based immunotherapy as strategy to purge the HIV reservoir?. <i>EBioMedicine</i> , 2019, 43, 16-17.	6.1	1
23	Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals. <i>Aids</i> , 2019, 33, 425-431.	2.2	31
24	In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. <i>Aids</i> , 2019, 33, 605-613.	2.2	21
25	Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits <i>Ex Vivo</i> Lipopolysaccharide-Induced Inflammatory Responses. <i>MSphere</i> , 2018, 3, .	2.9	17
26	Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 909-916.	3.3	15
27	Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
28	The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon. <i>Mucosal Immunology</i> , 2018, 11, 449-461.	6.0	31
29	Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin. <i>Aids</i> , 2018, 32, 1729-1731.	2.2	1
30	Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals. <i>Aids</i> , 2018, 32, 1793-1802.	2.2	10
31	Low- and high-protein diets do not alter <i>ex vivo</i> insulin action in skeletal muscle. <i>Physiological Reports</i> , 2018, 6, e13798.	1.7	7
32	Clinical Interventions in HIV Cure Research. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1075, 285-318.	1.6	16
33	Beyond antiretroviral therapy. <i>Aids</i> , 2017, 31, 1665-1667.	2.2	4
34	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. <i>Journal of Virology</i> , 2017, 91, .	3.4	14
35	Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2017, 64, 1686-1695.	5.8	122
36	Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. <i>Journal of Infection</i> , 2017, 75, 555-571.	3.3	29

#	ARTICLE	IF	CITATIONS
37	Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. <i>Aids</i> , 2017, 31, 771-779.	2.2	29
38	Risk and prognosis of bacteremia and fungemia among first-time kidney transplant recipients: a population-based cohort study. <i>Infectious Diseases</i> , 2017, 49, 286-295.	2.8	5
39	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017, 2, .	5.0	59
40	HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. <i>Aids</i> , 2016, 30, 713-721.	2.2	19
41	Risk and Prognosis of Bacteremia and Fungemia among Peritoneal Dialysis Patients: A Population-Based Cohort Study. <i>Peritoneal Dialysis International</i> , 2016, 36, 647-654.	2.3	10
42	Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research. <i>Journal of Translational Medicine</i> , 2016, 14, 44.	4.4	15
43	Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark. <i>American Heart Journal</i> , 2016, 182, 36-43.	2.7	23
44	Risk and outcome of pyelonephritis among renal transplant recipients. <i>BMC Infectious Diseases</i> , 2016, 16, 264.	2.9	27
45	Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. <i>Lancet HIV</i> , 2016, 3, e463-e472.	4.7	159
46	Broad activation of latent HIV-1 in vivo. <i>Nature Communications</i> , 2016, 7, 12731.	12.8	65
47	Reversal of Latency as Part of a Cure for HIV-1. <i>Trends in Microbiology</i> , 2016, 24, 90-97.	7.7	88
48	A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2016, 90, 4441-4453.	3.4	94
49	The potential role for romidepsin as a component in early HIV-1 curative efforts. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 447-450.	4.4	10
50	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days. <i>PLoS Pathogens</i> , 2016, 12, e1005740.	4.7	21
51	The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients. <i>Aids</i> , 2015, 29, 1195-1200.	2.2	20
52	Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0124547.	2.5	55
53	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission. <i>PLoS Pathogens</i> , 2015, 11, e1005000.	4.7	92
54	The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. <i>PLoS Pathogens</i> , 2015, 11, e1005142.	4.7	445

#	ARTICLE	IF	CITATIONS
55	Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	3.0	10
56	Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir. <i>Molecular Medicine</i> , 2015, 21, 337-345.	4.4	32
57	Risk and prognosis of <i>Staphylococcus aureus</i> bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 6.	2.9	48
58	Histone Deacetylase Inhibitor Romidepsin Inhibits De Novo HIV-1 Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3984-3994.	3.2	26
59	Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv037.	0.9	42
60	Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. <i>Journal of Virology</i> , 2015, 89, 10176-10189.	3.4	89
61	Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. <i>Sexual Health</i> , 2014, 11, 511.	0.9	25
62	Comparison of the immunogenicity of Cervarix [®] and Gardasil [®] human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1147-1154.	3.3	45
63	<i>Pneumocystis jirovecii</i> pneumonia in patients with end-stage renal disease: a comparison with the general population. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 704-711.	1.5	8
64	Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. <i>Lancet HIV</i> , 2014, 1, e13-e21.	4.7	542
65	Comparison of the Immunogenicity and Reactogenicity of Cervarix and Gardasil Human Papillomavirus Vaccines in HIV-Infected Adults: A Randomized, Double-Blind Clinical Trial. <i>Journal of Infectious Diseases</i> , 2014, 209, 1165-1173.	4.0	66
66	Risk of human papillomavirus-related cancers among kidney transplant recipients and patients receiving chronic dialysis - an observational cohort study. <i>BMC Nephrology</i> , 2013, 14, 137.	1.8	21
67	Severe bacterial non-aids infections in HIV-positive persons: Incidence rates and risk factors. <i>Journal of Infection</i> , 2013, 66, 439-446.	3.3	43
68	Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 790-799.	3.3	44
69	Comparison of HDAC inhibitors in clinical development. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 993-1001.	3.3	173
70	Central nervous system infections among individuals with and without end-stage renal disease. <i>Journal of Infection</i> , 2013, 67, 19-26.	3.3	4
71	Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients. <i>PLoS ONE</i> , 2013, 8, e62074.	2.5	49
72	Polysaccharide Responsiveness Is Not Biased by Prior Pneumococcal-Conjugate Vaccination. <i>PLoS ONE</i> , 2013, 8, e75944.	2.5	6

#	ARTICLE	IF	CITATIONS
73	Risk and Prognosis of Hospitalization for Pneumonia Among Individuals With and Without Functioning Renal Transplants in Denmark: A Population-Based Study. <i>Clinical Infectious Diseases</i> , 2012, 55, 679-686.	5.8	16
74	TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1042-1047.	3.3	15
75	Antiviral and Immunological Effects of Tenofovir Microbicide in Vaginal Herpes Simplex Virus 2 Infection. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1404-1411.	1.1	14
76	Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 108-114.	1.5	9
77	The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults. <i>PLoS ONE</i> , 2012, 7, e42307.	2.5	20
78	Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study. <i>BMJ, The</i> , 2012, 345, e5823-e5823.	6.0	25
79	Timing of Toll-Like Receptor 9 Agonist Administration in Pneumococcal Vaccination Impacts Both Humoral and Cellular Immune Responses as Well as Nasopharyngeal Colonization in Mice. <i>Infection and Immunity</i> , 2012, 80, 1744-1752.	2.2	8
80	Morbidity and Risk of Subsequent Diagnosis of HIV: A Population Based Case Control Study Identifying Indicator Diseases for HIV Infection. <i>PLoS ONE</i> , 2012, 7, e32538.	2.5	25
81	Risk Factors for Pneumococcal Nasopharyngeal Colonization Before and After Pneumococcal Conjugate Vaccination in Persons with HIV: Brief Report. <i>Current HIV Research</i> , 2012, 10, 252-255.	0.5	2
82	The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review. <i>HIV Medicine</i> , 2011, 12, 323-333.	2.2	62
83	Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2011, 6, e21275.	2.5	30
84	The clinical use of adjuvants in pneumococcal vaccination: Current status and future perspectives. <i>Hum Vaccin</i> , 2011, 7, 276-280.	2.4	5
85	Tenofovir Selectively Regulates Production of Inflammatory Cytokines and Shifts the IL-12/IL-10 Balance in Human Primary Cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 57, 265-275.	2.1	65
86	Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy. <i>Aids</i> , 2010, 24, 1315-1322.	2.2	26
87	Intraabdominal and retroperitoneal soft-tissue sarcomas - outcome of surgical treatment in primary and recurrent tumors. <i>World Journal of Surgical Oncology</i> , 2010, 8, 81.	1.9	14
88	Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: A Danish historical cohort study. <i>BMC Infectious Diseases</i> , 2010, 10, 124.	2.9	32
89	Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV-Infected Adults with a Toll-Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2010, 51, 42-50.	5.8	111
90	Transmission of HIV-1 Drug-Resistant Variants: Prevalence and Effect on Treatment Outcome. <i>Clinical Infectious Diseases</i> , 2010, 50, 566-573.	5.8	63

#	ARTICLE	IF	CITATIONS
91	Mortality after Hospitalization for Pneumonia among Individuals with HIV, 1995â€“2008: A Danish Cohort Study. PLoS ONE, 2009, 4, e7022.	2.5	19
92	Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admissionâ€”a randomized trial. Clinical Microbiology and Infection, 2009, 15, 481-487.	6.0	109
93	The relationship between diagnostic tests and case characteristics in Legionnairesâ€™ disease. Scandinavian Journal of Infectious Diseases, 2009, 41, 425-432.	1.5	15
94	Hospitalization for Pneumonia among Individuals With and Without HIV Infection, 1995â€“2007: A Danish Populationâ€“Based, Nationwide Cohort Study. Clinical Infectious Diseases, 2008, 47, 1345-1353.	5.8	83
95	Confounding May Lead to Overestimation of Pneumococcal Polysaccharide Vaccine Effectiveness among HIVâ€“Infected Individuals. Clinical Infectious Diseases, 2008, 47, 294-295.	5.8	5
96	A binational cohort study of ventilator-associated pneumonia in Denmark and Australia. Scandinavian Journal of Infectious Diseases, 2006, 38, 256-264.	1.5	3
97	CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy. Frontiers in Cellular and Infection Microbiology, 0, 12, .	3.9	1